Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 238-243

  Marconato, Laura ^a   Buracco, Paolo ^b   Aresu, Luca ^c  

^a Clinica Veterinaria dell'Orologio and Centra Oncologico Veterinario   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Clinical trials; Endpoints; Immunotherapy; Oncology; Targeted therapy; Veterinary

Indexed keywords

CANCER VACCINE;

CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GENE EXPRESSION PROFILING; GROWTH INHIBITION; IMMUNE RESPONSE; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASMS; PROCEDURES; STATISTICS AND NUMERICAL DATA; VETERINARY;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; IMMUNOTHERAPY; NEOPLASMS; RESEARCH DESIGN;

EID: 84937522587     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.02.020     Document Type: Review

References (69)

1. Aresu L., Aricò A., Comazzi S., Gelain M.E., Riondato F., Mortarino M., Morello E., Stefanello D., Castagnaro M. VEGF and MMP-9: Biomarkers for canine lymphoma. Veterinary and Comparative Oncology 2014, 12:29-36.
2. Aricò A., Ferraresso S., Bresolin S., Marconato L., Comazzi S., te Kronnie G., Aresu L. Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma. PLoS ONE 2014, 10.1371/journal.pone.0111817.
3. Beeram M., Patnaik A. Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics. Hematology/Oncology Clinics of North America 2002, 16:1089-1100.
4. Bergman P.J. Cancer immunotherapy. Veterinary Clinics of North America: Small Animal Practice 2010, 40:507-518.
5. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A.E., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 2003, 9:1284-1290.
6. Bidard F.C., Trédan O. Trends in cancer-targeted antibody-drug conjugates. Targeted Oncology 2014, 9:1-8.
7. Bilusic M., Gulley J.L. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunology, Immunotherapy 2012, 61:109-117.
8. Bodey B., Siegel S.E., Kaiser H.E. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Anticancer Research 1996, 16:661-674.
9. Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. The Veterinary Journal 2015, 10.1016/j.tvjl.2014.12.015.
10. Cannistra S.A. Challenges and pitfalls of combining targeted agents in phase I studies. Journal of Clinical Oncology 2008, 26:3665-3667.
11. Cavallo F., Calogero R.A., Forni G. Are oncoantigens suitable targets for anti-tumour therapy?. Nature Reviews. Cancer 2007, 7:707-713.
12. Denies S., Sanders N.N. Recent progress in canine tumor vaccination: Potential applications for human tumor vaccines. Expert Review of Vaccines 2012, 1:1375-1386.
13. Douthwaite J., Jermutus L. Exploiting directed evolution for the discovery of biologicals. Current Opinion in Drug Discovery and Development 2006, 8:268-275.
14. Eisenhauer E.A. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Annals of Oncology 1998, 9:1047-1052.
15. Eskens F.A., Verweij J. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: Facing the challenge of a proper study design. Critical Reviews in Oncology/Hematology 2000, 34:83-88.
16. Ferreira E., Gobbi H., Saraiva B.S., Cassali G.D. Columnar cell lesions of the canine mammary gland: Pathological features and immunophenotypic analysis. BMC Cancer 2010, 10:61.
17. Freidlin B., Simon R. Evaluation of randomized discontinuation design. Journal of Clinical Oncology 2005, 23:5094-5098.
18. Fukuoka H., Cooper O., Ben-Shlomo A., Mamelak A., Ren S.G., Bruyette D., Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Journal of Clinical Investigation 2011, 121:4712-4721.
19. Gama A., Gartner F., Alves A., Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009, 87:432-437.
20. Grillo-López A.J. Rituximab: An insider's historical perspective. Seminars in Oncology 2000, 27:9-16.
21. Grosenbaugh D.A., Leard A.T., Bergman P.J., Klein M.K., Meleo K., Susaneck S., Hess P.R., Jankowski M.K., Jones P.D., Leibman N.F., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 2011, 72:1631-1638.
22. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
23. Heller J. Epidemiological and statistical considerations for interpreting and communicating oncological clinical trials. The Veterinary Journal 2015, 10.1016/j.tvjl.2015.02.014.
24. Hoering A., LeBlanc M., Crowley J.J. Randomized phase III clinical trial designs for targeted agents. Clinical Cancer Research 2008, 14:4358-4367.
25. Hoos A. Evolution of end points for cancer immunotherapy trials. Annals of Oncology 2012, 23:47-52.
26. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., Urba W., Blumenstein B., Sacks N., Keilholz U., et al. A clinical development paradigm for cancer vaccines and related biologics. Journal of Immunotherapy 2007, 30:1-15.
27. Horig H., Pullman W. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. Journal of Translational Medicine 2004, 2:44.
28. Iezzi M., Quaglino E., Amici A., Lollini P.L., Forni G., Cavallo F. DNA vaccination against oncoantigens: A promise. Oncoimmunology 2012, 1:316-325.
29. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature Reviews. Cancer 2006, 6:714-727.
30. Impellizeri J.A., Howell K., McKeever K.P., Crow S.E. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. The Veterinary Journal 2006, 171:556-558.
31. Ito D., Brewer S., Modiano J.F., Beall M.J. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leukemia & Lymphoma 2014, 10.3109/10428194.2014.914193.
32. Jeglum K.A. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Veterinary Clinics of North America: Small Animal Practice 1996, 26:73-85.
33. Johnson J.R., Williams G., Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. Journal of Clinical Oncology 2003, 21:1404-1411.
34. Jubala C.M., Wojcieszyn J.W., Valli V.E., Getzy D.M., Fosmire S.P., Coffey D., Bellgrau D., Modiano J.F. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Veterinary Pathology 2005, 42:468-476.
35. Klopfleisch R. Personalised medicine in veterinary oncology: One to cure just one. The Veterinary Journal 2015, 10.1016/j.tvjl.2015.01.004.
36. Korn E.L. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. Journal of the National Cancer Institute 2004, 96:977-978.
37. Korn E.L., Arbuck S.G., Pluda J.M., Simon R., Kaplan R.S., Christian M.C. Clinical trial designs for cytostatic agents: Are new approaches needed?. Journal of Clinical Oncology 2001, 19:265-272.
38. Le Tourneau C., Lee J.J., Siu L.L. Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute 2009, 101:708-720.
39. Lesterhuis W.J., Haanen J.B., Punt C.J. Cancer immunotherapy - revisited. Nature Reviews Drug Discovery 2011, 10:591-600.
40. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
41. LoRusso P.M., Boerner S.A., Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clinical Cancer Research 2010, 16:1710-1718.
42. Mackiewicz J., Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. European Journal of Pharmacology 2009, 625:84-89.
43. Maniscalco L., Iussich S., Morello E., Martano M., Biolatti B., Riondato F., Della Salda L., Romanucci M., Malatesta D., Bongiovanni L., et al. PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncology. The Veterinary Journal 2013, 195:41-47.
44. Marconato L., Frayssinet P., Rouquet N., Comazzi S., Leone V.F., Laganga P., Rossi F., Vignoli M., Pezzoli L., Aresu L. Randomized, placebo-controlled, double-Blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clinical Cancer Research 2014, 20:668-677.
45. Mitchell L., Thamm D.H., Biller B.J. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Journal of Veterinary Internal Medicine 2012, 26:355-362.
46. Nguyen S.M., Thamm D.H., Vail D.M., London C.A. Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2013, 10.1111/vco.12032.
47. Nicolaides N.C., O'Shannessy D.J., Albone E., Grasso L. Co-development of diagnostic vectors to support targeted therapies and theranostics: Essential tools in personalized cancer therapy. Frontiers in Oncology 2014, 4:141.
48. Paller C.J., Bradbury P.A., Ivy S.P., Seymour L., LoRusso P.M., Baker L., Rubinstein L., Huang E., Collyar D., Groshen S., et al. Design of phase I combination trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research 2014, 20:4210-4217.
49. Pan X., Tsimbas K., Kurzman I.D., Vail D.M. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: A phase I dose-finding study. Veterinary and Comparative Oncology 2014, 10.1111/vco.12091.
50. Park J.W., Kerbel R.S., Kelloff G.J., Barrett J.C., Chabner B.A., Parkinson D.R., Peck J., Ruddon R.W., Sigman C.C., Slamon D.J. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clinical Cancer Research 2004, 10:3885-3896.
51. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. Journal of the National Cancer Institute 2004, 96:990-997.
52. Peruzzi D., Gavazza A., Mesiti G., Lubas G., Scarselli E., Conforti A., Bendtsen C., Ciliberto G., La Monica N., Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Molecular Therapy 2010, 18:1559-1567.
53. Raval R.R., Sharabi A.B., Walker A.J., Drake C.G., Sharma P. Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. Journal for Immunotherapy of Cancer 2014, 2:14.
54. Riccardo F., Iussich S., Maniscalco L., Lorda-Mayayo S., La Rosa G., Arigoni M., De Maria R., Gattino F., Lanzardo S., Lardone E., et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research 2014, 20:3753-3762.
55. Robat C., London C., Bunting L., McCartan L., Stingle N., Selting K., Kurzman I., Vail D.M. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: A phase I dose-finding study. Veterinary and Comparative Oncology 2012, 10:174-183.
56. Rosner G.L., Stadler W., Ratain M.J. Randomized discontinuation design: Application to cytostatic antineoplastic agents. Journal of Clinical Oncology 2002, 20:4478-4484.
57. Sabattini S., Mancini F.R., Marconato L., Bacci B., Rossi F., Vignoli M., Bettini G. EGFR overexpression in canine primary lung cancer: Pathogenetic implications and impact on survival. Veterinary and Comparative Oncology 2015, 10.1111/vco.12002.
58. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. Journal of the National Cancer Institute 2012, 104:599-613.
59. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004, 10:6759-6763.
60. Simon R.M., Steinberg S.M., Hamilton M., Hildesheim A., Khleif S., Kwak L.W., Mackall C.L., Schlom J., Topalian S.L., Berzofsky J.A. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. Journal of Clinical Oncology 2001, 19:1848-1854.
61. Singer J., Weichselbaumer M., Stockner T., Mechtcheriakova D., Sobanov Y., Bajna E., Wrba F., Horvat R., Thalhammer J.G., Willmann M., et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Molecular Immunology 2012, 50:200-209.
62. Singer J., Fazekas J., Wang W., Weichselbaumer M., Matz M., Mader A., Steinfellner W., Meitz S., Mechtcheriakova D., Sobanov Y., et al. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Molecular Cancer Therapeutics 2014, 13:1777.
63. Skipper H.E. Perspectives in cancer chemotherapy: Therapeutic design. Cancer Research 1964, 24:1295-1302.
64. Sorenmo K.U., Krick E., Coughlin C.M., Overley B., Gregor T.P., Vonderheide R.H., Mason N.J. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS ONE 2011, 6. e24167.
65. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opinion on Therapeutic Targets 2003, 7:215-234.
66. Turek M.M., Thamm D.H., Mitzey A., Kurzman I.D., Huelsmeyer M.K., Dubielzig R.R., Vail D.M. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Veterinary and Comparative Oncology 2007, 5:219-231.
67. Vail D.M. Cancer clinical trials: Development and implementation. Veterinary Clinics of North America: Small Animal Practice 2007, 37:1033-1057.
68. Williams G., Pazdur R., Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. Journal of Biopharmaceutical Statistics 2004, 14:5-21.
69. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nature Reviews. Cancer 2009, 9:28-39.